Repeat pull from proven relationships plus room left

Ascendis Pharma A/S (ASND) — this company's answers

The model's full reasoning — Q1 2018 call → NOWe need answer only YES or NO based on transcript. Need analyze. Question asks: Does management describe that counterparties the company has ALREADY SERVED AND PROVEN ITSELF WITH — existing customers, accounts, partners, members, or programs — are CURRENTLY, ON THEIR OWN INITIATIVE, TAKING OR COMMITTING TO MEANINGFULLY MORE from the company than they previously did (larger or earlier reorders, broader deployments, added sites, products, or scope, relationships stepped up to bigger phases), AND does management convey that these same relationships remain LIGHTLY PENETRATED — that what these counterparties have taken so far is still a small share of what they could take — so that the expansion now visible is early? Need answer YES when both halves come through in management's own words as one coherent, present-tense story. Otherwise NO. We need parse transcript. Company Ascendis Pharma, rare disease endocrinology pipeline. They have product candidates in clinical trials. "counterparties" could be patients, investigators, sites? Existing relationships? They mention fliGHt trial: "Our fliGHt trial is actively enrolling subjects and has been picking up steam. You'll recall that fliGHt evaluates TransCon growth hormone in subjects who switch from daily growth hormone providing more data on safety and tolerability... We currently have around 25 sites mainly in the U.S. nearly all of whom participated in our heiGHt trial. We are pleased with the response to fliGHt indicating interest on the part of patients and investigators to switch from daily to weekly growth hormone. fliGHt also enlarges our safety package... We are on track with our goal to complete enrollment of 150 subjects during the third quarter of this year. Additionally, we have been successfully rolling over the initial group of subjects from heiGHt sites to the enliGHten trial, our long-term extension study." This describes existing sites from heiGHt participating in fliGHt and enliGHten, i.e., existing investigators/patients taking more (switching to weekly, long-term extension). Is that "counterparties already served and proven itself with" - yes, sites and subjects who participated in heiGHt are now enrolling in fliGHt and enliGHten. They are taking more: switching from daily to weekly, long-term extension.

← Back to the full ASND analysis